Becton Dickinson pays $175M for misleading investors about flawed IV pump system
By 
Adrianne Appel2024-12-18T18:08:00
Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission (SEC) said.
Manufacturers are required to get approvals from the Food and Drug Administration (FDA) for complex medical devices like infusion pumps.
The FDA approval process involves submitting detailed data showing a device is safe and effective. BD, one of the largest device manufacturers in the world, with 70,000 employees, received 10 percent of its profits from sales of the pump.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleFormer ADM execs inflated operating profits, SEC alleges
Three former executives at Archer-Daniels-Midland intentionally misled investors by inflating the performance of the company’s Nutrition unit, the U.S. Securities and Exchange Commission has alleged.
-
News BriefInnovasis, execs settle false claims case for $12M
Medical device manufacturer Innovasis and two of its top executives agreed to pay a total of $12 million to settle allegations originally brought by a whistleblower that they paid kickbacks to physicians.
-
Blog
Becton, Dickinson & Co. promotes CECO to general counsel
Global medical technology firm Becton, Dickinson and Company announced the promotion of Chief Ethics and Compliance Officer Michelle Quinn to general counsel.
More from Regulatory Enforcement
-
ArticleCFTC sues states to assert exclusive jurisdiction over prediction markets
The Commodity Futures Trading Commission filed lawsuits against Arizona, Connecticut, and Illinois last week over the jurisdiction of prediction markets, which have gained popularity in the past year.
-
ArticleCMA holds companies responsible for false claims, fake reviews ‘throughout supply chain’
Companies face large fines if they spread false marketing claims or fake reviews about their products and services—as well as those by suppliers—under a toughened competition regime in the U.K. aimed at enhancing consumer protection.
-
ArticleFTC warns VISA and other processors that company policies may lead to debanking
Visa, Mastercard, PayPal, and Stripe have received letters from the Federal Trade Commission, warning the companies to end any policies or terms of service that may result in the “debanking” of customers.